A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Sonrotoclax (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Small cell lung cancer
- Focus Adverse reactions
- Sponsors BeiGene
- 31 May 2024 Planned End Date changed from 1 May 2024 to 1 Apr 2026.
- 31 May 2024 Planned primary completion date changed from 1 May 2024 to 1 Apr 2026.
- 17 Jan 2024 Status changed from recruiting to active, no longer recruiting.